Asset Details
Do you wish to reserve the book?
Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
Do you wish to request the book?
Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
2025
Overview
Background This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte‐to‐lymphocyte ratio [MLR], and platelet‐to‐lymphocyte ratio [PLR]) and the treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with afatinib. Methods The patients with NSCLC treated with afatinib between June 2014 and February 2018 were retrospectively reviewed. Their inflammatory biomarkers and clinical outcomes (progression‐free survival [PFS] and tumor response) were explored using univariate and multivariate analyses. Results Among 325 patients, those with an NLR >2.18, MLR >0.19, and PLR >177.73 had significantly worse PFS than those with lower values. After adjusting for performance status, stage, and liver metastasis, the PFS was still unfavorable for a baseline NLR >2.18, MLR >0.19, or PLR > 177.73. Among 188 patients with paired inflammatory values, those whose NLR decreased by >29.5%, MLR decreased by >57.9%, and PLR increased by <18.8% had significantly better PFS. After adjusting for performance status, stage, and liver metastasis, the PFS was significantly unfavorable for an NLR decrease of <29.5% and MLR decrease of <57.9%. Among the patients with tumor response, NLR, MLR, and PLR significantly decreased after treatment (all p < 0.05). Conclusions Our study presented the NLR, MLR, and PLR as prognostic factors for patients with NSCLC treated with afatinib. Further investigation into these markers representing the tumor microenvironment and their association with cancer status is crucial for evaluating prognosis and clinical outcomes in patients with NSCLC. EGFRm NSCLC patients (n = 325). EGFRm NSCLC patients (n = 188). Afatinib for 1–3 months. Unfavorable prognostic factors for PFS. Baseline inflammatory values. NLR >2.18, MLR >0.19. PLR >177.73. Changes of inflammatory values. NLR decrease of <29.5%. MLR decrease of <57.9%.
Publisher
John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
Subject
/ Aged
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Female
/ Humans
/ Lung Neoplasms - drug therapy
/ Male
/ monocyte‐to‐lymphocyte ratio
/ Mutation
/ neutrophil‐to‐lymphocyte ratio
/ Original
/ platelet‐to‐lymphocyte ratio
/ Tumors
